1. Scrip
  2. >>Business

Regeneron And Lilly Are Back With Better COVID-19 Antibody Data – But Still Face Medical Skepticism

New Variants Also Make SARS-CoV2 A Moving Target

 
• By Andrew McConaghie

After disappointing initially, Lilly and Regeneron are back with compelling data for their monoclonal antibody products, but still face challenges from new COVID-19 variants and medical skepticism.

Hospital Covid patient
New data suggests the antibody therapies can have a big impact in preventing infection, or preventing at-risk individuals being hospitalized with severe COVID-19. • Source: Getty Images

Developed on unprecedented timelines similar to the COVID-19 vaccines, monoclonal antibody therapies – once seen as central to the fight against SARS-CoV-2 – have only played a limited role so far since the US emergency use approvals of Regeneron and Eli Lilly’s products.

Now armed with new data, and seeking expanded emergency use authorizations (EUAs), that looks set to change soon; but the companies will still face challenges to the treatments truly assisting

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.